Analysts Set Expectations for APRE FY2025 Earnings

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at Wedbush issued their FY2025 earnings estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.78) per share for the year. Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. Wedbush also issued estimates for Aprea Therapeutics’ FY2026 earnings at ($0.58) EPS, FY2027 earnings at $0.31 EPS and FY2028 earnings at $1.12 EPS.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.20. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.15 million.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Aprea Therapeutics Price Performance

APRE opened at $2.20 on Friday. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $6.80. The company has a market capitalization of $11.96 million, a price-to-earnings ratio of -0.78 and a beta of 0.82. The business has a 50 day moving average price of $3.06 and a two-hundred day moving average price of $3.24.

Institutional Trading of Aprea Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $43,000. LPL Financial LLC acquired a new stake in shares of Aprea Therapeutics during the fourth quarter worth $53,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Aprea Therapeutics during the fourth quarter valued at $116,000. Finally, Stonepine Capital Management LLC boosted its position in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after purchasing an additional 12,047 shares during the period. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.